Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 9:46 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 37 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Alcohol spray Clear all

Conditions: Osteoarthritis (OA) of the Knee, Fear of Needles
Interventions: 25 gauge needle, 22 gauge needle, +/- Ethyl Chloride Topical Aerosol Anesthetic; Procedure
Lead sponsor: University of California, Davis; Other
Eligibility: 40 Years to 89 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Abscess
Interventions: Lidocaine, Vapocoolant; Drug
Lead sponsor: Albert Einstein Healthcare Network; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Covid19
Interventions: GSE and Xylitol, Control Placebo; Other · Drug
Lead sponsor: Larkin Community Hospital; Other
Eligibility: 18 Years to 90 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Miami, Florida

Conditions: Alcohol Use
Interventions: Oxytocin, Placebo; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Urticaria Chronic
Interventions: Placebo, 0.5 mg epinephrine, 1 mg epinephrine; Drug
Lead sponsor: ARS Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Glenview, Illinois • Cincinnati, Ohio

Conditions: Hemangioma
Interventions: topical timolol maleate, Pulsed dye laser; Drug · Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: Up to 3 Months
Enrollment: 126 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV Infections
Interventions: Adaptavir (monomeric DAPTA); Drug
Lead sponsor: Rapid Laboratories Inc.; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Asthma in Children
Interventions: Cholecalciferol, antihistamine, Azithromycin, emollient cream, Fluticasone Propionate, Asthma Controller Medication; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 6 Years to 17 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Alcoholism, Alcohol Related Disorders
Interventions: oxytocin, placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years to 50 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Alcohol Dependence
Interventions: Intranasal Oxytocin, Placebo; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 65 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Mydriasis
Interventions: Tropicamide 1%-Phenylephrine 2.5% ophthalmic solution (TR/PE), Tropicamide 1% ophthalmic solution (TR), Phenylephrine 2.5% ophthalmic solution (PE); Drug
Lead sponsor: Eyenovia Inc.; Industry
Eligibility: Not listed
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Cypress, California

Conditions: Gagging
Interventions: Anesthetic spray, Acupuncture, Masking Tape; Drug · Device · Genetic
Lead sponsor: Tufts University; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: PTSD, Alcohol Use Disorder
Interventions: 40 IU Intranasal Oxytocin, Placebo, Concurrent Treatment of PTSD and Substance Use Disorders using Prolonged Exposure; Drug · Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 70 Years
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Pain, Acute
Interventions: Intravenous oxytocin, Intravenous placebo, Intranasal oxytocin, Intranasal placebo; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Alcohol Use Disorder, Smoking
Interventions: Oxytocin nasal spray, Placebo; Drug
Lead sponsor: Brown University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Allergic Reactions
Interventions: Neffy, Adrenaline; Drug
Lead sponsor: ARS Pharmaceuticals, Inc.; Industry
Eligibility: 4 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 6
States / cities: La Jolla, California • Washington D.C., District of Columbia • Glenview, Illinois + 3 more

Conditions: Alcohol Use Disorder, Alcohol Misuse
Interventions: Instranasal Oxytocin; Drug
Lead sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA); NIH
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 4
States / cities: Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 1 more

Conditions: Food Allergy, Anaphylaxis, Food Hypersensitivity, Food Allergy Peanut
Interventions: Epinephrine Auto-Injector 0.3 mg/0.3 mL, Epinephrine 0.3 mg intramuscular manual injection via a syringe and needle, IN-001 9.06 mg Sublingual Spray, IN-001 13.59 mg Sublingual Spray; Drug
Lead sponsor: Insignis Therapeutics, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Opioid Use Disorder, Pregnancy Related, Substance Use, Drug Abuse, Drug Abuse in Pregnancy, Drug Addiction
Interventions: Personally-Tailored Opioid-overdose and Medication for opioid use disorder (MOUD) Education (TOME), Control; Behavioral
Lead sponsor: T. John Winhusen, PhD; Other
Eligibility: 18 Years and older · Female only
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 6
States / cities: Jacksonville, Florida • Pittsburgh, Pennsylvania • Charleston, South Carolina + 3 more

Conditions: Acute Respiratory Infections, Acute Rhinosinusitis
Interventions: Acetaminophen, Amoxicillin, Dextromethorphan hydrobromide with guaifenesin, Guaifenesin, Pseudoephedrine Sustained Action, Saline spray (0.65%); Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 70 Years
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Migraine Headache
Interventions: Propranolol or nadolol, Placebo control, Behavioral Migraine Management (BMM), Optimal Acute Therapy; Drug · Behavioral
Lead sponsor: Ohio University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 2
States / cities: Athens, Ohio • Westerville, Ohio

Conditions: Autonomic Failure, Orthostatic Hypotension
Interventions: Atomoxetine, Acarbose, Pyridostigmine Bromide, Yohimbine, Midodrine HCl, placebo, Modafinil, Octreotide, water intake, Diphenhydramine Hydrochloride, Ranitidine HCL, Tranylcypromine, Ergotamine/ Caffeine, Celecoxib, Pseudoephedrine, Methylphenidate, Indomethacin, Ibuprofen, Oxymetazoline 0.05% nasal solution, Bovril, Acetazolamide, Rivastigmine tartrate, Carbidopa/levodopa, Inflatable abdominal binder, inflatable abdominal binder (sham); Drug · Other · Dietary Supplement + 1 more
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 389 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Middle Ear Disease, Nasal Allergy
Interventions: ragweed, histamine, pseudoephedrine, Oxymetazoline; Biological · Drug
Lead sponsor: Cuneyt M. Alper; Other
Eligibility: 18 Years to 50 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Posttraumatic Stress Disorder, Anxiety Disorder
Interventions: Propranolol, Reactivation, Mifepristone, Intranasal oxytocin; Drug · Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 35 Years
Enrollment: 186 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Charlestown, Massachusetts

Search by objective public record fields.

Pain Perception During Intra-Articular Knee Joint Injection: What is the Effect of Needle Gauge and the Use of Ethyl Chloride?

Vapocoolant Spray for Numbing Small Boils Before Incision and Drainage

Impact of GSE and Xylitol (Xlear) on COVID-19 Symptoms and Time to PCR Negativisation in COVID-19 Patients

Oxytocin, Alcohol Craving, and Intimate Partner Aggression

An Outpatient Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria

A Clinical Trial of Pulsed-dye Laser Versus Timolol Topical Solution Versus Observation on the Growth of Hemangioma in Newborn

Safety and Efficacy of ADAPTAVIR's Ability to Eliminate Treatment-Resistant Infectious Virus in Peripheral Blood Mononuclear Cells (PBMCs)

Personalized Treatment Algorithms for Difficult-to-treat Asthma

Laboratory Studies on Oxytocin for Treatment of Alcohol Use Disorder

Oxytocin Treatment of Alcohol Dependence

Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation

Effective Interventions to Overcome Severe Gag Reflex

Oxytocin to Enhance Integrated Treatment for AUD and PTSD

Intranasal and Intravenous Oxytocin for Analgesia to Noxious Heat Pain

Alcohol and Cigarette Craving During Oxytocin Treatment

Study Evaluating the Safety and Efficacy of Neffy or Intramuscular Adrenalin in Patients With Allergic Reactions After Oral Food Challenge or Allergen Immunotherapy

Intranasal Oxytocin for the Treatment of Alcohol Use Disorder

PK/PD Study of IN-001 Sublingual Spray in Healthy Adults

Personally-Tailored Opioid-overdose and Medication for Opioid Use Disorder (MOUD) Education (TOME) for Pregnant and Postpartum Persons in MOUD

Treatment of Acute Sinusitis

Drug and Non-Drug Treatment Of Severe Migraine

Treatment of Orthostatic Hypotension in Autonomic Failure

TransMEM Gas Exchange -- Project 1, Aim 2

Pilot Study of Pharmaceutical and Behavioral Interventions to Treat Anxiety Disorders